@article {7089,
	title = {Emerging antibodies for the treatment of multiple myeloma},
	journal = {Expert Opinion on Emerging Drugs},
	volume = {21},
	year = {2016},
	note = {Export Date: 18 February 2017References: Weiner, G.J., Building better monoclonal antibody-based therapeutics (2015) Nat Rev Cancer, 15 (6), pp. 361-370;Weidle, U.H., Tiefenthaler, G., Weiss, E.H., The intriguing options of multispecific antibody formats for treatment of cancer (2013) Cancer Genomics Proteomics, 10 (1), pp. 1-18; 
Sapra, P., Shor, B., Monoclonal antibody-based therapies in cancer: advances and challenges (2013) Pharmacol Ther, 138 (3), pp. 452-469; 
Markham, A., Elotuzumab: first global approval (2016) Drugs; 
McKeage, K., Daratumumab: first global approval (2016) Drugs, 76 (2), pp. 275-281; 
http://seer.cancer.gov/statfacts/html/mulmy.html, Available from:, JanMoreau, P., San Miguel, J., Ludwig, H., Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2013) Ann Oncol, 24, pp. vi133-vi137; 
Moreau, P., Avet-Loiseau, H., Harousseau, J.L., Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies (2011) J Clin Oncol, 29, pp. 1898-1906; 
San Miguel, J.F., Schlag, R., Khuageva, N.K., Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (2008) N Engl J Med, 359, pp. 906-917; 
P{\"o}nisch, W., Mitrou, P.S., Merkle, K., Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone{\textemdash}a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO) (2006) J Cancer Res Clin Oncol, 132, pp. 205-212; 
Zagouri, F., Terpos, E., Kastritis, E., An update on the use of lenalidomide for the treatment of multiple myeloma (2015) Expert Opin Pharmacother, 16 (12), pp. 1865-1877; 
Rajkumar, S.V., Harousseau, J.L., Durie, B., Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 (2011) Blood, 117, pp. 4691-4695; 
Lemieux, E., Hulin, C., Caillot, D., Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma (2013) Biol Blood Marrow Transplant, 19, pp. 445-449; 
Orlowski, R.Z., Nagler, A., Sonneveld, P., Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression (2007) J Clin Oncol, 25, pp. 3892-3901; 
San Miguel, J., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial (2013) Lancet Oncol, 14 (11), pp. 1055-1066; 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372 (2), pp. 142-152. , Jan; 
Kumar, S.K., Berdeja, J.G., Niesvizky, R., Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study; 
Chanan-Khan, A.A., Borrello, I., Lee, K.P., Development of target-specific treatments in multiple myeloma (2010) Br J Haematol, 151 (1), pp. 3-15; 
Misso, G., Zappavigna, S., Castellano, M., Emerging pathways as individualized therapeutic target of multiple myeloma (2013) Expert Opin Biol Ther, 13, pp. S95-S109. , Jun; 
Lonial, S., Durie, B., Palumbo, A., Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives (2016) Leukemia; 
Moreaux, J., Legouffe, E., Jourdan, E., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone (2004) Blood, 103, pp. 3148-3157; 
Moreaux, J., Cremer, F.W., Reme, T., The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature (2005) Blood, 106, pp. 1021-1030; 
Descamps, G., Wuill{\`e}me-Toumi, S., Trichet, V., CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642 (2006) J Immunol, 177, pp. 4218-4223; 
Hsi, E.D., Steinle, R., Balasa, B., CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma (2008) Clin Cancer Res, 14, pp. 2775-2784. , {\textbullet} This study provides the preclinical data and the mechanism of action of elotuzumab and daratumumab, the two monoclonal antibodies that are currently approved by FDA; 
Tai, Y.T., Dillon, M., Song, W., Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu (2008) Blood, 112, pp. 1329-1337. , {\textbullet} This study provides the preclinical data and the mechanism of action of elotuzumab and daratumumab, the two monoclonal antibodies that are currently approved by FDA; 
Balasa, B., Yun, R., Belmar, N.A., Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways (2015) Cancer Immunol Immunother, 64 (1), pp. 61-73; 
van Rhee, F., Szmania, S.M., Dillon, M., Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma (2009) Mol Cancer Ther, 8 (9), pp. 2616-2624; 
Zonder, J.A., Mohrbacher, A.F., Singhal, S., A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma (2012) Blood, 120 (3), pp. 552-559; 
Richardson, P.G., Jagannath, S., Moreau, P., Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study (2015) Lancet Haematol, 2 (12), pp. e516-e527; 
Lonial, S., Vij, R., Harousseau, J.L., Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma (2012) J Clin Oncol, 30 (16), pp. 1953-1959; 
Lonial, S., Dimopoulos, M., Palumbo, A., Elotuzumab therapy for relapsed or refractory multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma (2015) N Engl J Med, 373 (7), pp. 621-631. , {\textbullet}{\textbullet} Based on the promising clinical data, elotuzumab is currently approved by FDA; 
Berdeja, J., Jagannath, S., Zonder, J., Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study (2016) Clin Lymphoma Myeloma Leuk; 
Usmani, S.Z., Sexton, R., Ailawadhi, S., Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 (2015) Blood Cancer J, 5, p. e334; 
Jakubowiak, A.J., Benson, D.M., Bensinger, W., Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma (2012) J Clin Oncol, 30 (16), pp. 1960-1965; 
Voorhees, P.M., Chen, Q., Small, G.W., Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death (2009) Br J Haematol, 145, pp. 481-490; 
van Zaanen, H.C.T., Lokhorst, H.M., Aarden, L.A., Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and solublegp130 (1998) Leuk Lymphoma, 31, pp. 551-558; 
Orlowski, R.Z., Gercheva, L., Williams, C., A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma (2015) Am J Hematol, 90, pp. 42-49; 
San-Miguel, J., Blad{\'e}, J., Shpilberg, O., Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma (2014) Blood, 123 (26), pp. 4136-4142; 
Voorhees, P.M., Manges, R.F., Sonneveld, P., A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma (2013) Br J Haematol, 161 (3), pp. 357-366; 
Hirata, T., Shimazaki, C., Sumikuma, T., Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro (2003) Leuk Res, 27 (4), pp. 343-349; 
Matsuyama, Y., Nagashima, T., Honne, K., Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab (2011) Intern Me, 50 (6), pp. 639-642; 
Allegra, A., Penna, G., Alonci, A., Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma (2013) Eur J Haematol, 90 (6), pp. 441-468; 
Fulciniti, M., Hideshima, T., Vermot-Desroches, C., A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma (2009) Clin Cancer Res, 15 (23), pp. 7144-7152; 
Moreau, P., Voillat, L., Benboukher, L., Rituximab in CD20 positive multiple myeloma (2007) Leukemia, 21 (4), pp. 835-836; 
Zojer, N., Kirchbacher, K., Vesely, M., Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma (2006) Leuk Lymphoma, 47, pp. 1103-1109; 
Baz, R., Fanning, S., Kunkel, L., Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma (2007) Leuk Lymphoma, 48 (12), pp. 2338-2344; 
Musto, P., Carella, A.M., Jr., Greco, M.M., Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation (2003) Br J Haematol, 123 (4), pp. 746-747; 
Lebovic, D., Kaminski, M.S., Anderson, T.B., A phase II study of consolidation treatment with iodione-131 tositumomab (BexxarTM) in multiple myeloma (MM) (2012) Blood (ASH Annual Meeting Abstracts), 120, p. 1854; 
Stein, R., Smith, M.R., Chen, S., Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines (2009) Clin Cancer Res, 15 (8), pp. 2808-2817; 
Kaufman, J.L., Niesvizky, R., Stadtmauer, E.A., Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma (2013) Br J Haematol, 163 (4), pp. 478-486; 
de Weers, M., Tai, Y.T., van der Veer, M.S., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors (2011) J Immunol, 186 (3), pp. 1840-1848. , {\textbullet} This study provides the preclinical data and the mechanism of action of elotuzumab and daratumumab, the two monoclonal antibodies that are currently approved by FDA; 
van der Veer, M.S., de Weers, M., van Kessel, B., The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies (2011) Blood Cancer J, 1 (10), p. e41; 
Lokhorst, H.M., Plesner, T., Laubach, J.P., Targeting CD38 with daratumumab monotherapy in multiple myeloma (2015) N Engl J Med, 373 (13), pp. 1207-1219; 
Lonial, S., Weiss, B.M., Usmani, S.Z., Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial (2016) Lancet, , {\textbullet}{\textbullet} Based on the promising clinical data, daratumumab is currently approved by FDA; 
Moreau, P., Mateos, M.V., Blade, J., An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma (2014) Blood, 124, p. 176. , {\textbullet}{\textbullet} Based on the promising clinical data, daratumumab is currently approved by FDA; 
Chari, A., Lonial, S., Suvannasankha, A., Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma (2015) Blood; 
Deckert, J., Wetzel, M.C., Bartle, L.M., SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies (2014) Clin Cancer Res, 20 (17), pp. 4574-4583; 
Jiang, H., Acharya, C., An, G., SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide (2016) Leukemia; 
Martin, T.G., Hsu, K., Strickland, S.A., A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma (2014) J Clin Oncol, 32, p. 5s; 
Martin, T.G., Baz, R., Benson, D.M., A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (2014) Blood, 124, p. 83; 
Raab, S., Goldschmidt, H.M., Agis, H., A phase I/IIa study of the human anti-CD38antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM) (2015) J Clin Oncol, 33S, p. 8574; 
Hassan, S.B., S{\o}rensen, J.F., Olsen, B.N., Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials (2014) Immunopharmacol Immunotoxicol, 36 (2), pp. 96-104. , Apr; 
Bensinger, W., Maziarz, R.T., Jagannath, S., A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma (2012) Br J Haematol, 159 (1), pp. 58-66; 
Hussein, M., Berenson, J.R., Niesvizky, R., A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma (2010) Haematologica, 95 (5), pp. 845-848; 
Tai, Y.T., Li, X.F., Catley, L., Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications (2005) Cancer Res, 65 (24); 
Agura, E., Niesvizky, R., Matous, J., Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study (2009) Blood (ASH Annual Meeting Abstracts), 114, p. 2870; 
Kamba, T., McDonald, D.M., Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007) Br J Cancer, 96 (12), pp. 1788-1795; 
Ria, R., Vacca, A., Russo, F., A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma (2004) Thromb Haemost, 92 (6), pp. 1438-1445; 
Koldehoff, M., Beelen, D.W., Elmaagacli, A.H., Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma (2008) J Leukoc Biol, 84 (2), pp. 561-576; 
Markovina, S., Callander, N.S., O{\textquoteright}Connor, S.L., Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells (2010) Mol Cancer, 9, p. 176; 
Somlo, G., Lashkari, A., Bellamy, W., Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial (2011) Br J Haematol, 154 (4), pp. 533-535; 
White, D., Kassim, A., Bhaskar, B., Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma (2013) Cancer, 119 (2), pp. 339-347; 
Callander, N.S., Markovina, S., Juckett, M.B., The addition of bevacizumab (B) to lenalidomide (L) and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma [abstract 3885] (2009) Blood, 114, p. 1495. , (ASH Annual Meeting Abstracts); 
Mahtouk, K., Jourdan, M., De Vos, J., An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis (2004) Blood, 103 (5), pp. 1829-1837; 
B{\"o}ll, B., Eichenauer, D.A., Von Tresckow, B., Activity of cetuximab as single agent in a patient with relapsed multiple myeloma (2010) Leuk Lymphoma, 51, pp. 562-564; 
Von Tresckow, B., Boell, B., Eichenauer, D., Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial (2014) Leuk Lymphoma, 55, pp. 695-697; 
Lacy, M.Q., Alsina, M., Fonseca, R., Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma (2008) J Clin Oncol, 26, pp. 3196-3203; 
Scartozzi, M., Bianconi, M., Maccaroni, E., Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer (2010) Curr Opin Mol Ther, 12, pp. 361-371; 
Descamps, G., Gomez-Bougie, P., Venot, C., A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 (2009) Br J Cancer, 100 (2), pp. 366-369; 
Moreau, P., Cavallo, F., Leleu, X., Phase I study of the anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (2011) Leukemia, 25 (5), pp. 872-874; 
Hengeveld, P.J., Kersten, M.J., B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? (2015) Blood Cancer J, 5, p. e282; 
Raje, N., Faber, E.A., Paul, G., Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma (2012) Blood (ASH Annual Meeting Abstracts), 120, p. 447; 
Xia, Y., Medeiros, L.J., Young, K.H., Immune checkpoint blockade: releasing the brake towards hematological malignancies (2015) Blood Rev, , Epub ahead of print; 
Cheah, C.Y., Fowler, N.H., Neelapu, S.S., Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma (2015) Curr Opin Oncol, 27, pp. 384-391; 
Ayed, A.O., Chang, L.-J., Moreb, J.S., Immunotherapy for multiple myeloma: current status and future directions (2015) Crit Rev Oncol Hematol, 96, pp. 399-412; 
Kretz-Rommel, A., Qin, F., Dakappagari, N., Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy (2008) J Immunol, 180, pp. 699-705; 
Conticello, C., Giuffrida, R., Parrinello, N., CD200 expression in patients with Multiple Myeloma: another piece of the puzzle (2013) Leuk Res, 37, pp. 1616-1621; 
Tai, Y.-T., Anderson, K.C., Targeting B-cell maturation antigen in multiple myeloma (2015) Immunotherapy, 7, pp. 1187-1199; 
Harada, T., Ozaki, S., Targeted therapy for HM1.24 (CD317) on multiple myeloma cells (2014) Biomed Res Int, 2014, p. 965384; 
Maes, K., De Smedt, E., Kassambara, A., In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma (2015) Oncotarget, 6, pp. 3319-3334; 
Sprynski, A.C., Hose, D., Caillot, L., The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor (2009) Blood, 113, pp. 4614-4626
},
	month = {2016},
	pages = {225 - 237},
	abstract = {ABSTRACT: Introduction: Monoclonal antibodies mark the beginning of a new era in the context of multiple myeloma (MM) treatment. Numerous antibodies have been tested or are currently in development for patients with MM, in order to improve tolerability and quality of life. Areas covered: This manuscript reviews emerging antibodies for the treatment of MM i.e. elotuzumab, daratumumab, MOR03087, isatuximab, bevacizumab, cetuximab, siltuximab, tocilizumab, elsilimomab, azintrel, rituximab, tositumomab, milatuzumab, lucatumumab, dacetuzumab, figitumumab, dalotuzumab, AVE1642, tabalumab, pembrolizumab, pidilizumab, nivolumab. Expert opinion: Amongst these antibodies, elotuzumab which targets SLAMF-7 and daratumumab which targets CD38, have been recently approved by FDA for patients with relapsed/refractory MM. Both agents are well tolerated. Multiple clinical trials incorporating these monoclonal antibodies in MM treatment are currently ongoing. Of special interest are the anticipated results of phase III clinical trials with elotuzumab [NCT0189164; NCT01335399; NCT02495922] and daratumumab [NCT02252172; NCT02195479] in newly diagnosed MM patients. Moreover, of great interest are the awaited data on pembrolizumabin combination with pomalidomide and dexamethasone in refractory/relapsed MM patients [NCT02576977] and in combination with lenalidomide and dexamethasone in newly diagnosed MM patients. It seems that the incorporation of monoclonal antibodies will change the landscape of myeloma therapy in the near future. {\textcopyright} 2016 Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {Daratumumab, Elotuzumab, monoclonal antibodies, multiple myeloma, targeted therapy},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975230032\&doi=10.1080\%2f14728214.2016.1186644\&partnerID=40\&md5=c621d63d5e6e6adf9c532a7e4c03f825},
	author = {Zagouri, F. and Terpos, E. and Kastritis, E. and Dimopoulos, M.A.}
}
